Ophthalmic biosimilars: Lessons from India

Indian J Ophthalmol. 2019 Aug;67(8):1384-1385. doi: 10.4103/ijo.IJO_430_19.

Authors

Ashish Sharma¹, Nilesh Kumar¹, Baruch D Kuppermann², Bandello Francesco³, Anat Lowenstein⁴

Affiliations

¹ Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India.
² Gavin Herbert Eye Institute, University of California, Irvine, CA, USA.
³ Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.
⁴ Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel.

No abstract available

Publication types

Letter

MeSH terms

Angiogenesis Inhibitors / adverse effects
Angiogenesis Inhibitors / pharmacology
Biosimilar Pharmaceuticals / adverse effects*
Biosimilar Pharmaceuticals / pharmacology*
Developing Countries
Endophthalmitis / chemically induced*
Humans
India
Ophthalmic Solutions / adverse effects*
Ophthalmic Solutions / pharmacology*
Pharmacovigilance*
Ranibizumab / adverse effects
Ranibizumab / pharmacology
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Biosimilar Pharmaceuticals
Ophthalmic Solutions
VEGFA protein, human
Vascular Endothelial Growth Factor A
Ranibizumab